Ex Parte Davis - Page 5


                  Appeal No. 2006-3204                                                               Page 5                     
                  Application No. 10/057,629                                                                                    

                  Appellant cites Hidaka,4 Nguyen5 and Salen,6 all of which teach that HMG-CoA                                  
                  reductase inhibitors such as lovastatin and pravastatin are ineffective in the                                
                  treatment of sitosterolemia.                                                                                  
                          Thus, Hidaka teaches that “[p]ravastatin had little effect in a sitosterolemic                        
                  patient on plasma levels of sterols, where cholestyramine decreased the plasma                                
                  levels of both cholesterol and cholestanol.”  Hidaka, abstract.  Salen teaches that                           
                  “[l]ovastatin, a competitive inhibitor of cholesterol biosynthesis that is widely used                        
                  in the treatment of hypercholesterolemia has been tried but has not been an                                   
                  effective treatment in sitosterolemia.”  Salen, page 952, paragraph bridging the                              
                  two columns.  Nguyen also teaches that lovastatin is “ineffective” in the treatment                           
                  in sitosterolemia.  Nguyen, page 1942, first column.  Moreover, Nguyen suggests                               
                  that differences in responses may be used diagnostically.  Specifically, Nguyen                               
                  teaches that “[t]he therapies with cholestyramine and lovastatin not only support                             
                  our contention of the fundamental abnormality in the regulation of cholesterol                                
                  biosynthesis that underlies sitosterolemia, but the response to these therapies                               
                  can also be used to detect sitosterolemia. . . .  Therefore, the failure to respond                           
                  to lovastatin and a substantial response to cholestyramine may suggest                                        
                  sitosterolemia . . . .”  Id. at page 1946, second column.                                                     


                                                                                                                                
                  4 Hidaka et al. (Hidaka), “Effects of an HMG-CoA Reductase Inhibitor, Prevastatin, and Bile                   
                  Sequestering Resin, Cholestyramine, on Plasma Plant Sterol Levels in Hypercholesterolemic                     
                  Subjects,” Journal of Atherosclerosis and Thrombosis, Vol. 2, No. 1, pp. 60-65 (1995).                        
                  5 Nguyen et al. (Nguyen), “Regulation of cholesterol biosynthesis in sitosterolemia: effects of               
                  lovastatin, cholestyramine, and dietary sterol restriction,” Journal of Lipid Research, Vol. 32,              
                  pp. 1941-48 (1991).                                                                                           
                  6 Salen et al. (Salen), “Sitosterolemia,” Journal of Lipid Research, Vol. 33, pp. 945-55 (1992).              




Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next

Last modified: September 9, 2013